menu

About
Ionis Innovation
- Overview
- Antisense Technology
- Optimizing Antisense
- Pipeline
- Ion-ARPA Initiative
Our Medicines
Patients & Community
- Overview
- Patient Resources
- Community Engagement
- Patient Experiences
Investors & media
- Overview
- Newsroom
  - Press Releases
  - InBriefs
  - Media Center
- Events
- Stock Information
  - Stock Quote & Chart
  - Analyst Coverage
  - Ownership Profile
- Financials
  - SEC Filings
  - Annual Reports
- Governance
  - Governance Documents
  - Committee Composition
  - RSU Holdings Guidelines
- Investor Resources
  - Investor FAQs
  - Contact Us
Careers
- Overview
- Working at Ionis
- Employee Spotlight
- Intern Program
- Post Doctoral Program

Investors & Media

Investor contact

760-603-2331

Media contact

760-603-4679

Year

Jan 18, 2022	Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
Jan 05, 2022	Ionis to present at 40th Annual J.P. Morgan Healthcare conference
Jan 04, 2022	Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

Akcea Therapeutics^® is a trademark of Ionis Pharmaceuticals, Inc.